Search

Barrie A Carter

from Laurel, MD
Age ~64
Get Report
Also known as:
Barrie Anthony Carter, Carter Barrie, Barrie A Carer, Kellie Stewart
Phone and address:
7101 Sandy Spring Rd, Laurel, MD 20707
(301) 483-8143
Related to:
Pamela L Carter, 63
Connected to:
Aandrea Carter, 58Adriel L Carter, 47Adriene D Carter, 42Aidan Carter, 28Alfreda M Carter, 65Alicia S Carter, 40Alise M Carter, 33Alissa D Carter, 40Alix N Carter, 28Alysa A Carter, 44

Barrie Carter Phones & Addresses

  • 7101 Sandy Spring Rd, Laurel, MD 20707 (301) 483-8143
  • 900 5Th St, Laurel, MD 20707
  • 3522 Edwards St, Uppr Marlboro, MD 20774 (301) 773-6511
  • Upper Marlboro, MD
  • Bayou Vista, TX

Resumes

Resumes

Barrie Carter Photo 1

Ecommerce Manager

View page
Location:
Laurel, MD
Industry:
Consumer Goods
Work:
A1 Affiliates of Md
Ecommerce Manager
Barrie Carter Photo 2

President

View page
Location:
Laurel, MD
Industry:
Internet
Work:
A1 Affiliates of Maryland
President
Trans America Insurance Agency Dec 2006 - Oct 2012
Insurance Agent
Anchor Construction Corporation Dec 2006 - Oct 2012
Utility Foreman
John Vitale and Sons Oct 2001 - Sep 2011
Utility Foreman
Aurthor L Hamel Construction Jun 1981 - Mar 2000
Contruction Foreman
Skills:
Management
Continuous Improvement

Publications

Isbn (Books And Publications)

Concepts in Genetic Medicine

View page
Author

Barrie Carter

ISBN #

0471703206

Us Patents

Modified Adeno-Associated Virus Vector Capable Of Expression From A Novel Promoter

View page
US Patent:
58666966, Feb 2, 1999
Filed:
Apr 3, 1996
Appl. No.:
8/626953
Inventors:
Barrie J. Carter - Kensington MD
Terence Flotte - Baltimore MD
Sandra Afione - Bethesda MD
Rikki Solow - Gaithersburg MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C07H 2104
US Classification:
536 235
Abstract:
Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.

Amino-Terminally Truncated Cystic Fibrosis Transmembrane Conductance Regulator

View page
US Patent:
59902795, Nov 23, 1999
Filed:
May 31, 1995
Appl. No.:
8/455552
Inventors:
Barrie J. Carter - Kensington MD
Terence Flotte - Baltimore MD
Sandra Afione - Bethesda MD
Rikki Solow - Gaithersburg MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C07K 1400
C12P 2106
US Classification:
530350
Abstract:
Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.

Modified Adeno-Associated Virus Vector Capable Of Expression From A Novel Promoter

View page
US Patent:
55873081, Dec 24, 1996
Filed:
Jun 2, 1992
Appl. No.:
7/891962
Inventors:
Barrie J. Carter - Kensington MD
Terence Flotte - Baltimore MD
Sandra Afione - Bethesda MD
Rikki Solow - Gaithersburg MD
Assignee:
The United States of America as represented by the Department of Health
& Human Services - Washington DC
International Classification:
C12N 510
C12N 1586
C07H 2104
US Classification:
4352402
Abstract:
Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.

Generation Of High Titers Of Recombinant Aav Vectors

View page
US Patent:
56587767, Aug 19, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/448613
Inventors:
Terence R. Flotte - Glen Burnie MD
Barrie J. Carter - Seattle WA
William B. Guggino - Baltimore MD
Rikki Solow - Gaithersburg MD
Assignee:
Targeted Genetics Corporation - Seattle WA
Johns Hopkins University - Baltimore MD
International Classification:
C12N 516
C12N 1564
C12N 1586
US Classification:
4351723
Abstract:
Adeno-associated virus (AAV) vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantifies of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. Stable, helper-free AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and reverses cellular immortalization. This invention provides packaging systems and processes for packaging AAV vectors that efficiently circumvent these problems by replacing the AAV p5 promoter with a heterologous promoter and that allow for substantially increased packaging efficiency.

Adeno-Associated Virus As Eukaryotic Expression Vector

View page
US Patent:
47973684, Jan 10, 1989
Filed:
Mar 15, 1985
Appl. No.:
6/712236
Inventors:
Barrie J. Carter - Kensington MD
Jon D. Tratschin - Berne, CH
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12N 700
C12N 1500
C12P 1934
C12P 2100
US Classification:
435320
Abstract:
The present invention relates to a vector comprising part of AAV DNA contained in a plasmid and capable of being packaged into AAV particles and functioning as a vector for stable integration and expression of a gene in eukaryotic cells when under control of an AAV transcription promoter. A method of preparing such plasmids which are packagable and rescuable is also described.

Modified Adeno-Associated Virus Vector Capable Of Expression From A Novel Promoter

View page
US Patent:
59895403, Nov 23, 1999
Filed:
May 31, 1995
Appl. No.:
8/455231
Inventors:
Barrie J. Carter - Kensington MD
Terence Flotte - Baltimore MD
Sandra Afione - Bethesda MD
Rikki Solow - Gaithersburg MD
Assignee:
The United States of America as represented by the Department of Health
& Human Services - Washington DC
International Classification:
A61K 4800
C12N 1564
C12N 1586
US Classification:
424 932
Abstract:
Described herein are constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences capable of functioning as a eukaryotic expression vector for expressing foreign DNA sequences using a novel transcription promoter comprising the termini of AAV DNA. It is shown that expression of a test reporter gene can be obtained from this vector in mammalian cells. It is further shown that this combination of vector and promoter can be used to introduce and express a human gene and correct a genetic defect in human cells resulting from malfunction of the mutant endogenous gene. Further, the vector can be used to correct the genetic defect by expressing a modified version of the human gene consisting of a fusion of part of the said gene and a synthetic sequence contained in the vector.
Control profile
Barrie A Carter from Laurel, MD, age ~64 Get Report